Molecular Health, TestAnalytika sign distribution agreement for TreatmentMAP in Latin American region

Molecular Health signed an agreement with TestAnalytika to be its preferred distributor in the Latin American region at the 2015 ASCO Annual Meeting. TestAnalytika will begin to market and distribute Molecular Health's cancer treatment decision support product, TreatmentMAP™, to patients, physicians, hospitals, laboratories, cancer centers and insurers in Latin America later this year.

Molecular Health CEO Lutz Voelker said, "We are pleased that TestAnalytika will bring the best personalized cancer treatment decision support available, TreatmentMAP, to patients across Latin America as Molecular Health's preferred distributor in this region."

TestAnalytika is bringing innovative integrated insurance solutions to the Latin American region to provide patients with access to advanced molecular genomic treatment support. TestAnalytika will also support patients who prefer to prepay or self-pay for these services.

TestAnalytika CEO Lin Giralt said, "TestAnalytika is going to provide cancer patients in Latin America with access to state of the art molecular cancer treatment decision support. International patients will no longer need to travel to the U.S. or Europe to receive these kinds of services. TestAnalytika will bring Molecular Health's TreatmentMAP to the patient's own physician enabling local personalized cancer treatment decisions."

TestAnalytika will launch these services in Latin America later this year.

SOURCE Molecular Health GmbH